Matthew Shawn Morris Sells 59,037 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 59,037 shares of Privia Health Group stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $27.33, for a total transaction of $1,613,481.21. Following the completion of the transaction, the director owned 76,651 shares in the company, valued at $2,094,871.83. This trade represents a 43.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Monday, July 6th, Matthew Shawn Morris sold 53,722 shares of Privia Health Group stock. The shares were sold at an average price of $27.24, for a total transaction of $1,463,387.28.
• On Monday, June 29th, Matthew Shawn Morris sold 63,212 shares of Privia Health Group stock. The shares were sold at an average price of $25.33, for a total transaction of $1,601,159.96.
• On Friday, June 26th, Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock. The shares were sold at an average price of $25.33, for a total value of $2,231,826.30.
• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The stock was sold at an average price of $24.99, for a total value of $427,229.04.
• On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The stock was sold at an average price of $24.96, for a total value of $25,384.32.

Privia Health Group Stock Down 0.1%

Shares of NASDAQ:PRVA opened at $27.21 on Thursday. The company has a market cap of $3.43 billion, a price-to-earnings ratio of 170.07, a PEG ratio of 2.15 and a beta of 0.83. The business has a 50 day moving average price of $23.65 and a 200 day moving average price of $23.08. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $27.70.

Hedge Funds Weigh In On Privia Health Group

Several hedge funds and other institutional investors have recently modified their holdings of PRVA. Durable Capital Partners LP boosted its stake in Privia Health Group by 1.8% in the 3rd quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock valued at $291,123,000 after buying an additional 203,842 shares in the last quarter. State Street Corp raised its stake in Privia Health Group by 1.5% during the second quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after acquiring an additional 61,853 shares in the last quarter. Van Berkom & Associates Inc. lifted its holdings in shares of Privia Health Group by 5.4% during the first quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock valued at $83,371,000 after acquiring an additional 208,787 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Privia Health Group by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock valued at $66,738,000 after acquiring an additional 31,204 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of Privia Health Group by 1.6% in the 4th quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock valued at $66,099,000 after purchasing an additional 43,589 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Barclays dropped their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Canaccord Genuity Group reduced their price objective on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a report on Friday, May 8th. Finally, Evercore set a $26.00 target price on shares of Privia Health Group in a research report on Wednesday, April 8th. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.15.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.